Sotaxim Injection (250mg, 500mg, 1g & 2g) - Broad-Spectrum 3rd Generation Cephalosporin Antibiotic

Product Overview

Sotaxim Injection is a broad-spectrum, high-potency parenteral third-generation cephalosporin antibiotic containing Cefotaxime Sodium. Engineered for immediate systemic bioavailability via Intravenous (IV) injection/infusion or Intramuscular (IM) injection, Sotaxim delivers rapid bactericidal action against a wide range of Gram-negative and Gram-positive bacterial pathogens. It is indicated for the clinical treatment of severe lower respiratory tract infections, bacterial meningitis, intra-abdominal infections, complicated urinary tract infections, bone and joint infections, pelvic inflammatory disease, bacteremia, and sepsis.

Key Benefits

\n
• \n

  Broad-Spectrum Bactericidal Efficacy: Highly active against susceptible Gram-negative organisms (including Enterobacteriaceae and Haemophilus influenzae) and Gram-positive pathogens (Streptococcus pneumoniae).

  \n
\n
• \n

  Excellent Blood-Brain Barrier Penetration: Penetrates inflamed meninges effectively, making it a reliable therapy for bacterial meningitis.

  \n
\n
• \n

  Rapid Systemic Bioavailability: Direct parenteral administration achieves immediate peak serum levels for critical inpatient care.

  \n
\n
• \n

  Flexible Strength Range (250mg to 2g): Supports precise dosing across pediatric, adult, and intensive surgical care regimens.

  \n
\n
• \n

  Surgical Prophylaxis Utility: Effectively prevents perioperative bacterial contamination in contaminated or high-risk surgical procedures.

  \n
\n

How It Works

Sotaxim Injection (Cefotaxime Sodium) exerts its bactericidal effect by binding to specific penicillin-binding proteins (PBPs) located on the inner membrane of the bacterial cell wall. This binding inhibits transpeptidase enzymes, preventing the cross-linking of peptidoglycan chains necessary for bacterial cell wall strength and integrity. The resulting structural instability causes osmotic lysis and rapid cell death of actively dividing bacterial cells.

WooCommerce Attribute / Variation Details

Variation 1: SOTAXIM 250MG INJ

\n
• \n

  SKU: SOT-INJ-250

  \n
\n
• \n

  Short Description: Ideal for pediatric patients, low-weight infants, and targeted light systemic dosing.

  \n
\n
• \n

  Key Active Ingredient: Cefotaxime Sodium — equivalent to 250mg Cefotaxime per vial.

  \n
\n
• \n

  Target Indications: Mild-to-moderate pediatric infections, neonatal bacteremia/meningitis protocols, and dose-adjusted renal care.

  \n
\n
• \n

  Standard Dosage: Administered via IV or IM every 8 to 12 hours according to pediatric weight-based dosing guidelines.

  \n
\n

Variation 2: SOTAXIM 500MG INJ

\n
• \n

  SKU: SOT-INJ-500

  \n
\n
• \n

  Short Description: Suitable for pediatric severe infections, moderate adult infections, and initial step-down antimicrobial regimens.

  \n
\n
• \n

  Key Active Ingredient: Cefotaxime Sodium — equivalent to 500mg Cefotaxime per vial.

  \n
\n
• \n

  Target Indications: Uncomplicated urinary tract infections, moderate respiratory tract infections, and pediatric systemic infections.

  \n
\n
• \n

  Standard Dosage: Administered via slow IV or IM every 8 to 12 hours as prescribed by a physician.

  \n
\n

Variation 3: SOTAXIM 1G INJ

\n
• \n

  SKU: SOT-INJ-1G

  \n
\n
• \n

  Short Description: Standard adult strength for moderate-to-severe systemic infections, pneumonia, and routine surgical prophylaxis.

  \n
\n
• \n

  Key Active Ingredient: Cefotaxime Sodium — equivalent to 1g Cefotaxime per vial.

  \n
\n
• \n

  Target Indications: Severe pneumonia, complicated skin/soft tissue infections, intra-abdominal sepsis, and pre-operative surgical prophylaxis.

  \n
\n
• \n

  Standard Dosage: Administered 1g IV or IM every 6 to 8 hours (or 1g IV prior to surgery for prophylaxis).

  \n
\n

Variation 4: SOTAXIM 2G INJ

\n
• \n

  SKU: SOT-INJ-2G

  \n
\n
• \n

  Short Description: High-potency clinical strength reserved for life-threatening infections, severe sepsis, and bacterial meningitis.

  \n
\n
• \n

  Key Active Ingredient: Cefotaxime Sodium — equivalent to 2g Cefotaxime per vial.

  \n
\n
• \n

  Target Indications: Bacterial meningitis, severe septicemia, infections in immunocompromised/neutropenic patients, and life-threatening intra-abdominal infections.

  \n
\n
• \n

  Standard Dosage: Administered 2g via slow IV infusion every 4 to 6 hours (maximum adult daily dose up to 12g).

  \n
\n

General Product Details (Shared across variations)

Key Active Ingredients

\n
• \n

  Cefotaxime Sodium (250mg / 500mg / 1g / 2g): Parenteral third-generation cephalosporin antibiotic that inhibits bacterial cell wall synthesis.

  \n
\n

Directions for Use

\n
1. \n

   Reconstitution: Reconstitute the sterile powder with Sterile Water for Injection or 0.9% Sodium Chloride Injection as follows:

   \n \n
   \n
   • \n

     IM Injection: Reconstitute with 2ml (for 250mg/500mg) or 4ml (for 1g/2g) of Sterile Water for Injection or 1% Lidocaine Hydrochloride solution (to reduce injection site pain). Never administer Lidocaine-reconstituted solution intravenously.

     \n
   \n
   • \n

     IV Injection/Infusion: Reconstitute with Sterile Water for Injection, then dilute further in 50ml to 100ml of compatible infusion solution (0.9% Sodium Chloride or 5% Dextrose).

     \n
   \n
   \n
\n
2. \n

   Administration:

   \n \n
   \n
   • \n

     IV Push: Administer reconstituted solution slowly over 3 to 5 minutes.

     \n
   \n
   • \n

     IV Infusion: Infuse over 20 to 60 minutes.

     \n
   \n
   • \n

     IM: Inject deeply into a large muscle mass (such as the upper outer quadrant of the gluteus maximus).

     \n
   \n
   \n
\n
3. \n

   Professional Healthcare Use: Must be administered exclusively by qualified medical personnel in a hospital or clinical setting.

   \n
\n

Precautions

\n
• \n

  Prescription-Only Parenteral: Strictly for professional healthcare administration; do not self-administer.

  \n
\n
• \n

  Cephalosporin & Penicillin Hypersensitivity: Screen patients carefully for prior allergic reactions to cephalosporins, penicillins, or other beta-lactam antibiotics. Cross-reactivity may occur.

  \n
\n
• \n

  Renal Impairment: Reduce dosing frequency in patients with severe renal impairment ($CL_{cr} < 20\text{ ml/min}$).

  \n
\n
• \n

  Gastrointestinal Toxicity: Monitor for signs of severe diarrhea or Clostridioides difficile-associated colitis during or following therapy.

  \n
\n
• \n

  Consult an attending physician before use during pregnancy or lactation.

  \n
\n
• \n

  Keep out of reach of children.

  \n
\n

Storage Instructions

Store the un-reconstituted dry powder vial in a cool, dry place below 30°C, protected from direct light and heat. Once reconstituted, the solution should be used immediately or within 12 to 24 hours if refrigerated between 2°C and 8°C. Do not freeze.

Manufacturer Information

Formulated and manufactured in strict compliance with international pharmaceutical quality standards, dedicated to producing high-grade anti-infective parenteral formulations to fight complex bacterial infections and enhance critical patient care.